Characterization of Hepatitis C Virus (HCV) Quasispecies Dynamics upon Short-Term Dual Therapy with the HCV NS5B Nucleoside Polymerase Inhibitor Mericitabine and the NS3/4 Protease Inhibitor Danoprevir

In the INFORM-1 study, 73 patients with chronic hepatitis C virus infection received mericitabine plus danoprevir for up to 13 days. Seventy-two patients experienced a continuous decline in HCV RNA levels during treatment, and of these patients, 14 had viral loads that remained >1,000 IU/ml by da...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Le Pogam, S., Yan, J. M., Chhabra, M., Ilnicka, M., Kang, H., Kosaka, A., Ali, S., Chin, D. J., Shulman, N. S., Smith, P., Klumpp, K., Nájera, I.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2012
Sujets:
Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3486584/
https://ncbi.nlm.nih.gov/pubmed/22869576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01035-12
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires